Cancer has been a constant companion since the dawn of life, becoming one of the greatest threats to human health. Despite humanity's continuous exploration and challenges in this battle against cancer, from initial fear and helplessness to today's proactive treatment and prevention, our understanding and research of cancer have made significant progress.
In humanity's relentless fight against cancer, Agaricus blazei, with its unique medicinal value and anti-cancer effects, has gradually become a focus of scientific research. Recently, a major breakthrough has been achieved in 45 years of research on Agaricus blazei, bringing new hope for cancer treatment.
The anti-cancer story of Agaricus blazei
Agaricus blazei, native to Brazil in South America, is hailed as "God's mushroom." In 1975, the Iwade Mycology Research Institute in Japan successfully cultivated Agaricus blazei artificially, laying the foundation for its widespread application.
For many years, the Japanese Society for Bacteriology, the Japanese Cancer Society, and other related societies and organizations have conducted in-depth research on the antitumor polysaccharides of Agaricus blazei (Iwaide 101 strain) and its extracts. These studies cover multiple aspects, including the isolation and purification of polysaccharides, bioactivity assessment, and the elucidation of antitumor mechanisms.
Based on research focus and direction, the research history of Agaricus blazei can be divided into six stages. The first stage, from 1980 to 1983, mainly focused on the antitumor activity of Agaricus blazei and its extracts. The second stage, from 1984 to 1987, explored the specific antitumor mechanisms of Agaricus blazei and its derived polysaccharide ATOMO. The third stage, from 1988 to 1992, revealed the effects of Agaricus blazei polysaccharides on different types of cancer cells and their promoting effect on immune cells. The fourth stage, from 1993 to 2002, discovered that Agaricus blazei extract has a regulatory effect on the immune system. The fifth stage, from 2003 to 2012, demonstrated the protective effect of Agaricus blazei extract against radiation damage and its ability to induce apoptosis in cancer cells. The sixth stage, from 2013 to the present, focuses on the inhibitory effect of Agaricus blazei polysaccharides on the expression of immune checkpoint molecules and the activation effect on dendritic cells.
Numerous research reports indicate that Agaricus blazei and its extracts have significant applications in cancer treatment. They not only enhance the body's immunity and natural healing abilities but also attack cancer cells, inhibiting their growth and spread. For example, studies have found that Agaricus blazei polysaccharides can promote the maturation of dendritic cells, enhancing the immune system's ability to recognize and attack cancer cells; Agaricus blazei extract can also inhibit cancer cell immune escape mechanisms, improve radiotherapy efficacy, and reduce radiation damage.
Natural Immune Checkpoint Inhibitors: A New Hope for Cancer Treatment
The turning point in Agaricus blazei's anti-cancer properties can be traced back to several important medical discoveries.
The true anti-cancer research on Agaricus blazei began with the pioneering efforts of a group of Japanese scientists. The Iwade Mycology Institute in Japan, founded by Professor Inosuke Iwade, is renowned for its significant achievements in the development and research of Agaricus blazei. In 1965, Professor Iwade's team, in collaboration with Mie University, successfully cultivated Agaricus blazei artificially. This mushroom, originally from Brazil, has been proven to have significant effects on immune regulation and anti-cancer activity due to its rich nutritional components and remarkable biological activity.
The turning point came in 2018 when Tasuku Honjo, a distinguished professor at Kyoto University, was awarded the Nobel Prize in Physiology or Medicine for his discovery of the immune checkpoint molecule PD-1. This discovery revealed how cancer cells suppress immune cells through the immune checkpoint mechanism, thereby evading the immune system's attack. This discovery spurred the development of immune checkpoint inhibitors, such as nivolumab and dotalimab, which have shown significant efficacy in clinical treatment, bringing new hope to cancer patients.
Building upon Professor Tasuku Honjo's research findings, the Institute of Mycology at Iwade Research Institute, through continuous research on Agaricus blazei, finally discovered an effective component with immune checkpoint inhibitory effects within the cell wall of Agaricus blazei. This discovery makes it the world's first naturally derived immune checkpoint inhibitor, opening new avenues for cancer treatment.
SCOPHIL Mushroom Extract CP-101: A unique R&D patent in the market.
Although Agaricus blazei is highly regarded for its anti-cancer properties, research has found that direct consumption does not effectively extract its key components. Traditional extraction methods also fail to effectively extract components with immune checkpoint blocking effects. To address this, Mie University and the Institute of Mycology have developed a new supercritical fluid extraction technology. This technology can efficiently extract key components from Agaricus blazei, producing a subcritical water extract, CP-101.
In 2022, the manufacturing method of Agaricus blazei subcritical water extract CP-101 was patented. This patent not only affirms the advanced nature and market uniqueness of the technology, but also recognizes SCOPHIL's decades of dedication to the field of cancer. This means that SCOPHIL's CP-101 subcritical water extract is unique and exclusive globally, providing consumers with a reliable quality guarantee.
Prevention and treatment: a two-pronged approach
SCOPHIL mushroom extract CP-101 not only demonstrates outstanding performance in treating cancer, but also shows great potential in preventing the occurrence and recurrence of cancer. Its immune checkpoint inhibition effect can effectively enhance the body's immunity, enabling the immune system to recognize and eliminate cancer cells earlier and more effectively, thus preventing the occurrence of cancer.
During cancer treatment, SCOPHIL mushroom extract CP-101 enhances the immune system's ability to attack cancer, complementing traditional therapies, significantly improving treatment effectiveness, and reducing the likelihood of recurrence. Furthermore, its natural ingredients and gentle properties make it an ideal choice for long-term prevention of cancer recurrence.
Previous clinical trial results have shown that Scophil mushroom extract CP-101 has significant effects in cancer treatment and rehabilitation.
In a clinical trial of acute non-lymphocytic leukemia, 20 patients were randomly divided into an Agaricus blazei group (experimental group) and a control group, with 10 patients in each group. After treatment, the Agaricus blazei group showed significant increases in peripheral blood hemoglobin, platelet count, and total white blood cell count, while the control group showed no significant changes, indicating that Agaricus blazei can improve peripheral blood counts. Furthermore, the Agaricus blazei group showed a significant increase in plasma albumin and a decrease in globulin, with an increased albumin/globulin ratio, while the control group showed no significant changes, indicating that Agaricus blazei achieves its anti-cancer effect through immunomodulation. Simultaneously, the Agaricus blazei group showed a significant increase in IgM after treatment, while the control group showed significant decreases in IgG, IgM, and IgE, indicating that Agaricus blazei enhances the body's immune function. Regarding symptoms and signs, the Agaricus blazei group showed significant improvement in mental state and appetite, fewer and milder toxic side effects from chemotherapy, and a significantly reduced number of infections.
In a case of prostate cancer treatment, a 76-year-old patient experienced immediate improvement in his physical discomfort symptoms the day after consuming Agaricus blazei extract from Iwae 101, and his PSA level dropped rapidly over the following six months.
In clinical breast cancer treatment cases, a 44-year-old patient experienced a partial spontaneous detachment of the tumor after taking Agaricus blazei, creating conditions for surgical treatment, and ultimately recovered and returned to work; a 43-year-old patient experienced a tumor shrinkage and almost disappearance after taking Agaricus blazei.
Clinical medical cases show that Agaricus blazei has demonstrated amazing effects in the treatment and rehabilitation of cancer patients. It can reduce the toxic side effects of chemotherapy drugs, improve the efficacy of chemotherapy, enhance human immunity, and inhibit the growth and spread of tumor cells, opening up a new future for the prevention and treatment of cancer.
The above clinical case content references "Clinical observation of Agaricus blazei on acute non-lymphocytic leukemia" (from "Journal of Lanzhou Medical College, Vol. 20, No. 3, 1994") and "Study on the inhibitory effect of polysaccharide-protein compounds extracted from Agaricus blazei 101 on the growth of acute leukemia Molt4B cells" (from "Medicine and Biology, Vol. 140, No. 3, 2000").
in conclusion
SCOPHIL Mushroom Extract CP-101, derived from the miraculous mushrooms of nature, has brought a revolutionary breakthrough to the fight against cancer. Its emergence marks a significant step forward in humanity's battle against cancer, injecting new vitality and hope. As a representative of natural immune checkpoint inhibitors, SCOPHIL Mushroom Extract CP-101 will undoubtedly play a vital role in humanity's victory over cancer.
